A Covidien study has shown that its new VenaSeal system is just as effective in treating chronic leg vein disorders as its ClosureFast ablation catheter.
Medtronic is reportedly preparing to float $10 billion worth of bonds to help fund its $43 billion acquisition of Covidien.
Here's a look at some of the top Wall Street stories for medical device companies this week: Medtronic inks $16B loan package for Covidien buyout; Second Sight eyes $32m IPO; The silver lining for healthcare in U.S. inversion rules; Survey: Hospitals clamp down on medical device expenses; Nevro boosts IPO to $126m
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic inks $16B loan package for Covidien buyout; The silver lining for healthcare in U.S. inversion rules; SV Life Sciences buys majority stake in Ximedica; Wright Medical slashes losses, Q3 sales surge; Salix inventory snafu sinks deal with Allergan
Medtronic agrees to concessions to mollify European anti-trust regulators over its $43 billion buyout of Covidien.
The director of the Fogarty Institute, medtech legend Dr. Tom Fogarty, shoots off some fireworks at MassMEDIC's 18th annual Medtech Showcase.
In the 50 years since Dr. Tom Fogarty invented the catheter-based treatment for blood clots that's now the standard of care, he's founded more than 30 medical device startups, placing him among the most prolific inventors in the biomedical space.
Forgarty is also, without a doubt, the industry's best quote.
Medtronic inks a package of loans worth more than $16 billion to back its $43 billion acquisition of Covidien.